PROSPECTIVE, MULTI-CENTER PHASE III TRIAL OF TUMOR TREATING FIELDS TOGETHER WITH TEMOZOLOMIDE COMPARED TO TEMOZOLOMIDE ALONE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA

被引：0

作者：

Stupp, Roger ^{[1
,2
]}

Idbaih, Ahmed ^{[3
]}

Steinberg, David M. ^{[4
]}

Read, William ^{[5
]}

Toms, Steven ^{[6
]}

Barnett, Gene ^{[7
]}

Nicholas, Garth ^{[8
]}

Kim, Chae-Yong ^{[9
]}

Fink, Karen ^{[10
]}

Salmaggi, Andrea ^{[11
]}

Lieberman, Frank ^{[12
]}

Zhu, Jay ^{[13
]}

Taylor, Lynne ^{[14
]}

Stragliotto, Giuseppe ^{[15
]}

Hottinger, Andreas ^{[16
]}

Kirson, Eilon D. ^{[17
]}

Weinberg, Uri

Palti, Yoram ^{[17
]}

Hegi, Monika E. ^{[16
]}

Ram, Zvi ^{[18
]}

机构：

[1] Univ Hosp Zurich, Zurich, Switzerland

[2] Univ Zurich, Zurich, Switzerland

[3] Grp Hosp Pitie Salpetriere, Paris, France

[4] Tel Aviv Univ, Tel Aviv, Israel

[5] Emory Univ Hosp Midtown, Atlanta, GA USA

[6] Geisinger Med Ctr, Danville, PA 17822 USA

[7] Cleveland Clin Fdn, 9500 Euclid Ave, Cleveland, OH 44195 USA

[8] Ottawa Hosp Res Inst, Ottawa, ON, Canada

[9] Seoul Natl Univ Bundang, Seoul, South Korea

[10] Baylor Charles A Sammons Canc Ctr, Dallas, TX USA

[11] Ist Natl Neurol Carlo Besta, Milan, Italy

[12] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA

[13] Mem Hermann Hosp, Houston, TX USA

[14] Tufts Med Ctr, Boston, MA USA

[15] Karolinska Hosp, Stockholm, Sweden

[16] CHU Vaudois, Lausanne, Switzerland

[17] Novocure Ltd, Haifa, Israel

[18] Tel Aviv Sourasky Med Ctr, Tel Aviv, Israel

来源：

NEURO-ONCOLOGY | 2016年 / 18卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LTBK-01

引用

页码：1 / 1

页数：1

共 50 条

[31] Maintenance Therapy with Tumor-Treating Fields plus Temozolomide vs Temozolomide alone for Glioblastoma. A Randomized Clinical Trial
Gervais, C.
Feuvret, L.
ONCOLOGIE, 2016, 18 (05) : 355 - 357
[32] Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma A Randomized Clinical Trial
Stupp, Roger
Taillibert, Sophie
Kanner, Andrew
Read, William
Steinberg, David M.
Lhermitte, Benoit
Toms, Steven
Idbaih, Ahmed
Ahluwalia, Manmeet S.
Fink, Karen
Di Meco, Francesco
Lieberman, Frank
Zhu, Jay-Jiguang
Stragliotto, Giuseppe
Tran, David D.
Brem, Steven
Hottinger, Andreas F.
Kirson, Eilon D.
Lavy-Shahaf, Gitit
Weinberg, Uri
Kim, Chae-Yong
Paek, Sun-Ha
Nicholas, Garth
Burna, Jordi
Hirte, Hal
Weller, Michael
Palti, Yoram
Hegi, Monika
Ram, Zvi
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2017, 318 (23): : 2306 - 2316
[33] COST EFFECTIVENESS OF TREATING GLIOBLASTOMA PATIENTS AGE 65 YEARS OR OLDER WITH TUMOR TREATING FIELDS PLUS TEMOZOLOMIDE VERSUS TEMOZOLOMIDE ALONE
Guzauskas, Gregory
Wang, Bruce C. M.
Pollom, Erqi
Stieber, Volker W.
Garrison, Lou
NEURO-ONCOLOGY, 2018, 20 : 116 - 117
[34] COST EFFECTIVENESS OF TREATING GLIOBLASTOMA PATIENTS AGE 65 YEARS OR OLDER WITH TUMOR TREATING FIELDS PLUS TEMOZOLOMIDE VERSUS TEMOZOLOMIDE ALONE
Guzauskas, G. F.
Wang, B. C. M.
Pollom, E. L.
Stieber, V. W.
Kinzel, A.
Proescholdt, C.
Garrison, L.
NEURO-ONCOLOGY, 2018, 20 : 254 - 254
[35] Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme
Athanassiou, H
Synodinou, M
Maragoudakis, E
Paraskevaidis, M
Verigos, C
Misailidou, D
Antonadou, D
Saris, G
Beroukas, K
Karageorgis, P
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (10) : 2372 - 2377
[36] PriCoTTF: A phase I/II single-arm trial of tumor treating fields prior and concomitant with radiotherapy and temozolomide in newly diagnosed glioblastoma
Glas, M.
Scheffler, B.
Lazaridis, L.
Herrlinger, U.
Pierscianek, D.
El Hindy, N.
Sure, U.
Proescholdt, M.
Hau, P.
Hense, J.
Kleinschnitz, C.
Combs, S. E.
Grosu, A. -L.
Stuschke, M.
Kebir, S.
STRAHLENTHERAPIE UND ONKOLOGIE, 2018, 194 : S73 - S73
[37] Tumor treating fields and maintenance temozolomide for newly-diagnosed glioblastoma: a cost-effectiveness study
Guzauskas, Gregory F.
Pollom, Erqi L.
Stieber, Volker W.
Wang, Bruce C. M.
Garrison, Louis P., Jr.
JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (10) : 1006 - 1013
[38] Scalp-sparing radiation with concurrent temozolomide and tumor treating fields (SPARE) for patients with newly diagnosed glioblastoma.
Miller, Ryan C.
Song, Andrew Jehyun
Ali, Ayesha
Bar-Ad, Voichita C.
Martinez, Nina Leyson
Glass, Jon
Alnahhas, Iyad
Andrews, David W.
Judy, Kevin
Evans, James J.
Farrell, Christopher
Werner-Wasik, Maria
Chervoneva, Inna
Ly, Michele
Palmer, Joshua David
Liu, Haisong
Shi, Wenyin
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[39] STANDARD OF CARE TEMOZOLOMIDE CHEMOTHERAPY ± TUMOR TREATING FIELDS (TTFIELDS) IN NEWLY DIAGNOSED GLIOBLASTOMA. FINAL RESULTS OF THE PHASE III EF-14 CLINICAL TRIAL
Stupp, R.
Ram, Z.
NEURO-ONCOLOGY, 2017, 19 : 15 - 15
[40] Tumor treating fields plus temozolomide for newly diagnosed glioblastoma: a sub-group analysis of Korean patients in the EF-14 phase 3 trial
Chae-Yong Kim
Sun Ha Paek
Do-hyun Nam
Jong-Hee Chang
Yong-Kil Hong
Jeong Hoon Kim
Oh Lyong Kim
Se-Hyuk Kim
Journal of Neuro-Oncology, 2020, 146 : 399 - 406

← 1 2 3 4 5 →